{"id":22449,"date":"2024-02-05T12:12:07","date_gmt":"2024-02-05T11:12:07","guid":{"rendered":"https:\/\/ggba.swiss\/geneuro-secures-eur-5-million-to-advance-post-covid-and-neurodegenerative-disease-treatments\/"},"modified":"2024-02-05T12:15:06","modified_gmt":"2024-02-05T11:15:06","slug":"geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/","title":{"rendered":"GeNeuro l\u00e8ve EUR 5 millions pour faire avancer les traitements post-COVID et des maladies neurod\u00e9g\u00e9n\u00e9ratives"},"content":{"rendered":"\n<p><a href=\"https:\/\/geneuro.com\/fr\/accueil\">GeNeuro<\/a>, soci\u00e9t\u00e9 biopharmaceutique bas\u00e9e \u00e0 Gen\u00e8ve et connue pour ses travaux pionniers dans le domaine des maladies neurod\u00e9g\u00e9n\u00e9ratives et auto-immunes, notamment la scl\u00e9rose en plaques (SEP), la scl\u00e9rose lat\u00e9rale amyotrophique (SLA) et les graves cons\u00e9quences neuropsychiatriques du COVID-19 (post-COVID), a proc\u00e9d\u00e9 avec succ\u00e8s \u00e0 une augmentation de capital de EUR 5 millions. Ce mouvement financier strat\u00e9gique a \u00e9t\u00e9 facilit\u00e9 par un placement priv\u00e9 destin\u00e9 \u00e0 des investisseurs sp\u00e9cialis\u00e9s et strat\u00e9giques, \u00e9mettant 4&rsquo;666&rsquo;901 nouvelles actions nominatives, ainsi que par une offre publique \u00e0 des investisseurs individuels en France via la plateforme PrimaryBid, totalisant 95&rsquo;004 nouvelles actions.<\/p>\n\n\n\n<p>Les nouvelles actions, d&rsquo;une valeur nominale de CHF 0,05, ont \u00e9t\u00e9 offertes \u00e0 un prix de vente de EUR 1,05, incluant la valeur nominale et la prime. Bryan, Garnier &amp; Co a agi en tant qu&rsquo;unique coordinateur global et teneur de livre pour cette op\u00e9ration. Cette lev\u00e9e de fonds repr\u00e9sente une \u00e9tape importante pour GeNeuro dans l&rsquo;ach\u00e8vement de son \u00e9tude de phase 2 en cours dans les conditions post-COVID, qui a d\u00e9j\u00e0 finalis\u00e9 le recrutement des patients en novembre de l&rsquo;ann\u00e9e derni\u00e8re, et dont les r\u00e9sultats sont attendus avec impatience en juin 2024.<\/p>\n\n\n\n<p>Jes\u00fas Martin-Garcia, CEO de GeNeuro, a soulign\u00e9 l&rsquo;importance de cette \u00e9tape financi\u00e8re : \u00ab&nbsp;Cette augmentation de capital r\u00e9ussie donne \u00e0 GeNeuro les moyens de terminer notre \u00e9tude de phase 2 post-COVID en cours, \u00e9tendant ainsi la visibilit\u00e9 financi\u00e8re de la soci\u00e9t\u00e9. Notre programme post-COVID avec <a href=\"https:\/\/geneuro.com\/fr\/patients-fr\/francais\">le temelimab<\/a> repr\u00e9sente la premi\u00e8re approche th\u00e9rapeutique personnalis\u00e9e dans cette indication, en se concentrant uniquement sur les patients positifs pour la prot\u00e9ine pathog\u00e8ne W-ENV.&nbsp;\u00bb<\/p>\n\n\n\n<p>Fait notable, des actionnaires de premier plan tels que GNEH SAS (filiale de l&rsquo;Institut M\u00e9rieux) et Servier ont particip\u00e9 au placement priv\u00e9, renfor\u00e7ant ainsi leur engagement dans l&rsquo;approche innovante de GeNeuro pour le traitement des maladies auto-immunes et neurod\u00e9g\u00e9n\u00e9ratives. Apr\u00e8s l&rsquo;offre, GNEH d\u00e9tiendra 40,2% du capital et 40,5% des droits de vote, tandis que Servier d\u00e9tiendra 8,4% du capital et 8,5% des droits de vote, sur une base non dilu\u00e9e.<\/p>\n\n\n\n<p>Le produit net de cette offre, ainsi que les r\u00e9serves de tr\u00e9sorerie actuelles de GeNeuro, sont principalement affect\u00e9s au financement de l&rsquo;ach\u00e8vement de l&rsquo;\u00e9tude post-COVID de phase 2 et \u00e0 l&rsquo;extension de la marge de man\u0153uvre financi\u00e8re de la soci\u00e9t\u00e9 jusqu&rsquo;au d\u00e9but du troisi\u00e8me trimestre de l&rsquo;ann\u00e9e 2024. Parall\u00e8lement, GeNeuro poursuit ses discussions dans le domaine de la scl\u00e9rose en plaques afin d&rsquo;identifier la voie de d\u00e9veloppement optimale pour combiner un traitement anti-inflammatoire efficace avec le temelimab, ciblant la neurod\u00e9g\u00e9n\u00e9rescence et la propagation des handicaps.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GeNeuro, soci\u00e9t\u00e9 connue pour ses travaux pionniers dans le domaine des maladies neurod\u00e9g\u00e9n\u00e9ratives et auto-immunes, vient de proc\u00e9der avec succ\u00e8s \u00e0 une augmentation de capital de EUR 5 millions.<\/p>\n","protected":false},"author":6,"featured_media":22446,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1217,1148,1171],"class_list":["post-22449","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-covid-19-fr-2","tag-financing-fr-2","tag-pharma-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GeNeuro l\u00e8ve EUR 5 millions ses traitements post-COVID | GGBa<\/title>\n<meta name=\"description\" content=\"GeNeuro, connu pour ses travaux dans le domaine des maladies neurod\u00e9g\u00e9n\u00e9ratives et auto-immunes, a augment\u00e9 son capital de EUR 5 millions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GeNeuro l\u00e8ve EUR 5 millions ses traitements post-COVID | GGBa\" \/>\n<meta property=\"og:description\" content=\"GeNeuro, connu pour ses travaux dans le domaine des maladies neurod\u00e9g\u00e9n\u00e9ratives et auto-immunes, a augment\u00e9 son capital de EUR 5 millions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-05T11:12:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-05T11:15:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/GeNeuro-Covid-Virus-1024x704.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"704\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"GeNeuro l\u00e8ve EUR 5 millions pour faire avancer les traitements post-COVID et des maladies neurod\u00e9g\u00e9n\u00e9ratives\",\"datePublished\":\"2024-02-05T11:12:07+00:00\",\"dateModified\":\"2024-02-05T11:15:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/\"},\"wordCount\":484,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/GeNeuro-Covid-Virus.jpeg\",\"keywords\":[\"Biotech\",\"Covid-19\",\"Financing\",\"Pharma\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/\",\"name\":\"GeNeuro l\u00e8ve EUR 5 millions ses traitements post-COVID | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/GeNeuro-Covid-Virus.jpeg\",\"datePublished\":\"2024-02-05T11:12:07+00:00\",\"dateModified\":\"2024-02-05T11:15:06+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"GeNeuro, connu pour ses travaux dans le domaine des maladies neurod\u00e9g\u00e9n\u00e9ratives et auto-immunes, a augment\u00e9 son capital de EUR 5 millions.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/GeNeuro-Covid-Virus.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/GeNeuro-Covid-Virus.jpeg\",\"width\":2360,\"height\":1622,\"caption\":\"La mission de GeNeuro est d'exploiter la biologie des r\u00e9trovirus endog\u00e8nes humains pour d\u00e9velopper des traitements s\u00fbrs et efficaces pour les patients.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GeNeuro l\u00e8ve EUR 5 millions pour faire avancer les traitements post-COVID et des maladies neurod\u00e9g\u00e9n\u00e9ratives\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GeNeuro l\u00e8ve EUR 5 millions ses traitements post-COVID | GGBa","description":"GeNeuro, connu pour ses travaux dans le domaine des maladies neurod\u00e9g\u00e9n\u00e9ratives et auto-immunes, a augment\u00e9 son capital de EUR 5 millions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/","og_locale":"fr_FR","og_type":"article","og_title":"GeNeuro l\u00e8ve EUR 5 millions ses traitements post-COVID | GGBa","og_description":"GeNeuro, connu pour ses travaux dans le domaine des maladies neurod\u00e9g\u00e9n\u00e9ratives et auto-immunes, a augment\u00e9 son capital de EUR 5 millions.","og_url":"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-02-05T11:12:07+00:00","article_modified_time":"2024-02-05T11:15:06+00:00","og_image":[{"width":1024,"height":704,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/GeNeuro-Covid-Virus-1024x704.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"GeNeuro l\u00e8ve EUR 5 millions pour faire avancer les traitements post-COVID et des maladies neurod\u00e9g\u00e9n\u00e9ratives","datePublished":"2024-02-05T11:12:07+00:00","dateModified":"2024-02-05T11:15:06+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/"},"wordCount":484,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/GeNeuro-Covid-Virus.jpeg","keywords":["Biotech","Covid-19","Financing","Pharma"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/","url":"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/","name":"GeNeuro l\u00e8ve EUR 5 millions ses traitements post-COVID | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/GeNeuro-Covid-Virus.jpeg","datePublished":"2024-02-05T11:12:07+00:00","dateModified":"2024-02-05T11:15:06+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"GeNeuro, connu pour ses travaux dans le domaine des maladies neurod\u00e9g\u00e9n\u00e9ratives et auto-immunes, a augment\u00e9 son capital de EUR 5 millions.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/GeNeuro-Covid-Virus.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/GeNeuro-Covid-Virus.jpeg","width":2360,"height":1622,"caption":"La mission de GeNeuro est d'exploiter la biologie des r\u00e9trovirus endog\u00e8nes humains pour d\u00e9velopper des traitements s\u00fbrs et efficaces pour les patients."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/geneuro-leve-eur-5-millions-pour-faire-avancer-les-traitements-post-covid-et-des-maladies-neurodegeneratives\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"GeNeuro l\u00e8ve EUR 5 millions pour faire avancer les traitements post-COVID et des maladies neurod\u00e9g\u00e9n\u00e9ratives"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/22449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=22449"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/22449\/revisions"}],"predecessor-version":[{"id":22451,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/22449\/revisions\/22451"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/22446"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=22449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=22449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=22449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}